Messaoudi, Nouredin
Henault, David
Stephen, David
Cousineau, Isabelle
Simoneau, Eve
Rong, Zhixia
Létourneau, Richard
Plasse, Marylène
Dagenais, Michel
Roy, André
Lapointe, Réal
Vandenbroucke-Menu, Franck
Kunda, Rastislav
Ysebaert, Dirk
Soucy, Geneviève
Stagg, John
Vermeulen, Peter http://orcid.org/0000-0003-4301-4528
Turcotte, Simon http://orcid.org/0000-0002-9003-812X
Article History
Received: 28 January 2021
Revised: 24 October 2021
Accepted: 2 December 2021
First Online: 3 January 2022
Competing interests
: JS is a permanent member of the scientific advisory board of Surface Oncology and holds stocks of Surface Oncology. ST is receiving non-clinical research funding from Bristol-Myers Squibb, clinical research funding from GlaxoSmithKline, Iovance Biotherapeutics and Turnstone Biologics. All other authors report no conflicts of interest concerning this specific publication.
: This study was approved by the comité d'éthique de la recherche of the Centre hospitalier de l’Université de Montréal, Montreal, QC, Canada. Informed consent of individual patients was obtained. This study was performed in accordance with the Declaration of Helsinki.